Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LB PHARMACEUTICALS INCLBRX · Entity 4678 | Director | June 03, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LB PHARMACEUTICALS INC
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.95 · Expires 2036-06-02 | Direct | 10,000 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 10,000 · Balance 10,000 F1: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 5, 2026 21:32 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $27.95 | $0.00 |
DisclosureSEC source: 0002031342-26-000002 · form4-06052026_090613.xml · derivative · entry 1 Luse Rebecca · CIK 0002031342 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-06-02 F1 · derivative.exercise_date: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantStock Option (Right to Buy) · Derivative | 22,449 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001415889-25-024451 · form4-09122025_060917.xml · derivative · entry 1 Luse Rebecca · CIK 0002031342 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,449 Underlying: Common Stock · 22,449 shares Expires 2035-09-09 F1 · derivative.exercise_date: The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.